10-K: Beauty Health Navigates Macro Headwinds, Focuses on Syndeo 3.0 & Consumables Growth

The Beauty Health Company reported a 10% decrease in net sales for 2025, driven by lower Delivery System sales, while improving gross margin and reducing operating losses amidst strategic debt restructuring and ongoing legal challenges.

Summary

• Net sales decreased by $33.5 million, or 10.0%, to $300.8 million for the year ended December 31, 2025, compared to $334.3 million in 2024.
• Delivery Systems net sales decreased by $37.3 million, or 29.8%, to $88.1 million in 2025, impacted by unfavorable macroeconomic and credit conditions across all regions.
• Consumables net sales increased by $3.8 million, or 1.8%, to $212.7 million in 2025, primarily due to increased placements of Delivery Systems and price increases, partially offset by declines related to the China market transition.
• Gross profit increased by $14.1 million, or 7.7%, to $196.4 million in 2025 from $182.3 million in 2024.
• Gross margin improved to 65.3% in 2025 from 54.5% in 2024, primarily due to lower inventory-related charges and a favorable mix shift towards consumable net sales.
• Loss from operations significantly narrowed to $20.8 million in 2025 from $67.8 million in 2024.
• Net loss decreased to $9.5 million in 2025 from $29.1 million in 2024.
• Cash, cash equivalents, and restricted cash totaled $232.7 million as of December 31, 2025, down from $370.1 million at December 31, 2024.
• The company repurchased $20.0 million principal amount of 2026 Notes for $18.4 million in 2025, recognizing a net gain of $1.5 million.
• An aggregate of $413.2 million principal amount of 2026 Notes were exchanged and repurchased in May 2025, including $263.2 million principal amount exchanged for $250.0 million principal amount of new 7.95% Convertible Senior Secured Notes due November 15, 2028, resulting in a net gain of $16.6 million.
• The Syndeo Enhancement Program, addressing performance issues with Syndeo 1.0 and 2.0 devices, was completed as of December 31, 2024.
• The company is subject to a formal SEC investigation related to allegations in a securities class action lawsuit concerning Syndeo 1.0 and 2.0 device performance.
• Multiple patent infringement lawsuits are ongoing, with some settlements reached, and an initial determination in the ITC Cartessa Matter found Hydrafacial's patent valid and infringed.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for the company, marked by declining sales and ongoing losses, despite improvements in gross margin and strategic debt management. The numerous legal and regulatory risks, coupled with macroeconomic headwinds, indicate significant uncertainty.

Positives

• Gross margin significantly improved to 65.3% in 2025 from 54.5% in 2024, driven by lower inventory-related charges and a favorable mix shift towards consumables.
• Operating loss was substantially reduced to $20.8 million in 2025, a significant improvement from $67.8 million in 2024.
• Net loss decreased to $9.5 million in 2025 from $29.1 million in 2024, indicating progress in profitability.
• Successfully restructured a portion of its debt by exchanging $263.2 million of 2026 Notes for $250.0 million of new 2028 Notes, extending maturity and realizing a net gain of $16.6 million.
• The Syndeo Enhancement Program, addressing previous device performance issues, was completed as of December 31, 2024, with Syndeo 3.0 showing significant improvement in user experience and decline in return rates.
• An initial determination in the ITC Cartessa Matter found Hydrafacial's patent valid and infringed by Cartessa's products, recommending an exclusion order and cease and desist order.
• Settlements were reached in several patent and trademark infringement cases (Medical Purchasing Resource, LLC, Luvo Medical Technologies Inc, Med Spa Essentials, LLC), resolving disputes and securing monetary damages or cessation of infringing activities.
• A previously reported material weakness in internal control over financial reporting was remediated during the fourth quarter of 2025.
• Net cash provided by operating activities increased to $37.5 million in 2025 from $16.1 million in 2024.

Negatives

• Total net sales decreased by 10.0% year-over-year, from $334.3 million in 2024 to $300.8 million in 2025.
• Delivery Systems net sales experienced a significant decline of 29.8% in 2025, attributed to unfavorable macroeconomic and credit conditions.
• Consumables sales growth was modest at 1.8%, partially offset by declines related to the transition of the China market to a distributor partner.
• The company continues to report operating losses ($20.8 million in 2025) and net losses ($9.5 million in 2025), indicating it is not yet consistently profitable.
• Interest expense increased by $8.9 million, or 85.6%, in 2025, primarily due to the higher interest rate (7.95%) on the newly issued 2028 Notes.
• Interest income decreased by $7.7 million, or 46.2%, in 2025 due to lower average invested balances.
• Cash, cash equivalents, and restricted cash decreased by $137.3 million from $370.1 million in 2024 to $232.7 million in 2025.
• The company has $124.5 million of 2026 Notes classified as current liabilities, maturing in October 2026, posing a near-term debt obligation.
• The FDA missed the December 29, 2025 deadline to promulgate final regulations implementing Good Manufacturing Practices (GMPs) for cosmetics, creating regulatory uncertainty.

Risks

• The beauty health industry is highly competitive and rapidly changing, with new product introductions, pricing pressures, and technological advances (including AI) posing challenges.
• Business is dependent on the commercial success and ability to sell Delivery Systems; failure to commercialize or significant performance interruptions could materially harm results.
• New product introductions may not be as successful as anticipated, as evidenced by past issues with Syndeo 1.0 and 2.0 devices.
• Damage to reputation or brand from product quality issues, adverse publicity, or failure to meet ethical/social standards could materially affect the business.
• Reliance on third-party suppliers, distributors, and delivery service providers introduces risks of failure to meet standards, supply restrictions, increased costs, or regulatory non-compliance.
• Maintaining single supply relationships for certain key components could lead to production interruptions or delays if supply is restricted or ceases.
• Ineffective inventory management may result in inventory obsolescence, value decline, and significant write-downs or write-offs.
• Disruption to the manufacturing and assembly facility in Long Beach, California, could negatively impact product manufacturing and distribution.
• Inability to hire, effectively train, manage, improve productivity of, and retain sales professionals could harm future revenue and profitability.
• Providers are not under obligation to purchase products, and business challenges at one or more providers could adversely affect results.
• Inability to repay or refinance existing debt obligations (2026 Notes, 2028 Notes) could lead to substantial liquidity problems or default.
• If cash from operations is insufficient, the company may need additional financing, which could dilute stockholders or impose restrictive covenants.
• Volatility in the financial markets could make future financings difficult or more expensive.
• Changes in tax law, tax rates, or exposure to additional income tax liabilities could materially affect the business.
• Fluctuations in currency exchange rates may negatively affect financial condition and results of operations.
• Impairment of goodwill or long-lived assets could require a significant charge to earnings.
• Increasing dependence on information technology exposes the company to risks of service interruptions, data corruption, cyber-based attacks, or network security breaches.
• Products may contain undetected errors or result in failures, leading to negative publicity, delays, or claims.
• Failure to adopt new technologies or adapt e-commerce websites and systems to changing consumer demands could materially affect the business.
• Privacy and data protection laws (e.g., GDPR, CCPA, CPRA, PIPL, MHMD, AI regulations) increase compliance burden and risk of regulatory enforcement, fines, or litigation.
• Payment methods used on e-commerce websites subject the company to third-party payment processing-related risks, including fraud and compliance with PCI DSS.
• Challenges with properly managing the use of AI could result in harm to the brand, reputation, business, or customers.
• International sales and operations expose the company to foreign operational, political, and economic risks, including local instability, trade restrictions, and intellectual property protection issues.
• Conducting business in China exposes the company to labor cost increases, regulatory changes, and intellectual property risks.
• Legal, political, and economic uncertainty surrounding Brexit continues to be a source of instability and uncertainty.
• Changes in the United States political environment, including government shutdowns and policy changes at regulatory agencies like the FDA, could negatively affect the business.
• New laws, regulations, enforcement trends, or changes in existing regulations governing the introduction, marketing, and sale of products could harm the business.
• Changes in regulations or enforcement trends regarding the scope of practice of estheticians could limit their ability to provide treatments.
• Extensive and continuing regulatory compliance obligations for medical devices and cosmetics; failure to obtain/maintain clearances or comply with requirements could harm commercial operations.
• Use, misuse, or off-label use of products may harm reputation, result in product liability suits, or lead to costly investigations, fines, or sanctions.
• Products may cause or contribute to adverse medical events or other undesirable side effects, requiring reporting to regulatory authorities; failure to report or product recalls could have a negative impact.
• Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government agencies could hinder product development and commercialization.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws could adversely affect the business.
• Failure to comply with the U.S. FCPA, other anti-corruption and anti-bribery laws, and applicable trade control laws could subject the company to penalties.
• Increasing costs and decreasing selling prices due to intense competition, inflationary pressure, and customer demands could cause operating margin to decline.
• Intellectual property rights may not provide adequate protection, may be difficult to enforce, or could be challenged by third parties.
• Reliance on licenses to use third-party intellectual property rights carries risks if licenses are not maintained or licensors infringe others' rights.
• Third parties may assert ownership or commercial rights to inventions developed or acquired by the company.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Use of social media may materially and adversely affect reputation or subject the company to fines or other penalties.
• Reliance on email and other messaging services for marketing; restrictions or inability to deliver communications could adversely affect net revenue.
• Corporate citizenship and sustainability matters, if not met, could result in additional costs, risks, and adverse impact on reputation.
• Future offerings of debt or equity securities may adversely affect the market price of Class A Common Stock and dilute stockholders' percentage ownership.
• If securities or industry analysts cease to publish research, or publish inaccurate or unfavorable research, the price of Class A Common Stock and trading volume could decline.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of Class A Common Stock.
• Significant numbers of outstanding securities (convertible notes, warrants) may result in significant dilution to current stockholders and downward pressure on stock price.
• Outstanding warrants are accounted for as liabilities, and changes in their fair value could have a material effect on financial results.
• Securities litigation is expensive to defend and could divert management's attention.
• Actions of activist stockholders could be costly and time-consuming, divert management's attention, and have an adverse effect on the business.
• No dividends are intended to be paid for the foreseeable future, meaning gains depend solely on stock price appreciation.

Future Outlook

The company anticipates continued fluctuations in future quarterly and annual operating results due to factors such as customer activity, product mix, economic conditions, manufacturing costs, and competition. It expects to incur additional operating losses for the foreseeable future, despite significant investments in product development, sales, marketing, and administrative programs. The company plans to increase its international sales and presence, particularly in high-growth markets, and will continue to invest in technology infrastructure, omnichannel capabilities, and data-driven analytics. Management believes it has sufficient liquidity for the next 12 months but will continuously evaluate capital expenditure needs based on various business and economic factors. Regulatory changes, such as the delayed finalization of cosmetic GMPs by the FDA and the ongoing legislative process for EU Medical Devices Regulation amendments, introduce uncertainty regarding future compliance requirements and market access.

Management Comments

• "We believe Hydrafacial treatments are accessible and appropriate for consumers across all genders, ages, skin types, and skin tones."
• "We believe the instant gratification provided by our Hydrafacial treatment generates high consumer and provider affinity for our brand."
• "Our strategic objective is to establish BeautyHealth as a leader in medical aesthetics by delivering an integrated ecosystem of solutions that combine devices, consumables, clinical credibility, and brand strength to achieve superior skin health outcomes for consumers and positive economic outcomes for providers."
• "We believe our platform benefits from several foundational advantages, including a globally recognized brand, a large installed base of Hydrafacial systems across provider practices worldwide, and a consumables-driven economic model that should generate meaningful operating leverage when utilization increases."
• "Our strategy is focused on unlocking the full economic potential of these assets by strengthening commercial execution, increasing utilization across our installed base, and continuing to invest in clinically meaningful innovation."
• "We believe the next phase of growth requires greater discipline, segmentation, and performance management."
• "We are working to refine the positioning of Hydrafacial as a clinically credible skin health platform supported by science, outcomes, and provider education."
• "We believe it represents the foundation of a broader skin health platform."
• "We believe our efforts to expand our brand recognition, cultivate our BeautyHealth community, invest in marketing capabilities, and activate consumers across channels will allow us to compete effectively as we continue to expand globally."
• "We are focused on expanding the beauty health category and creating a premier beauty health experience."
• "We believe that our operations are substantially in compliance with all applicable laws and regulations and that we hold all necessary permits to operate our business in each jurisdiction in which our facilities are located."
• "We believe effectively prioritizing and managing our ESG topics will create long-term value for our stakeholders, including our providers, consumers, suppliers, and partners, which in turn will create long-term value for our stockholders."
• "We believe we continue to maintain strong employee relations, which is consistent with employee feedback we received in prior years and reinforced through ongoing employee interactions and communication channels."
• "We believe that the claims asserted in the Securities Class Action have no merit and intends to vigorously defend them."
• "We believe that the claims asserted in the Customer Class Action have no merit and it intends to vigorously defend them."
• "Management believes that we have sufficient liquidity to satisfy our anticipated working capital requirements for our ongoing operations and obligations for at least the next 12 months."

Industry Context

StockSavvy.ai notes that The Beauty Health Company operates within a highly competitive and fragmented global medical aesthetics industry. The industry is characterized by evolving consumer behavior prioritizing skin health, demand for non-invasive treatments, and increasing provider adoption of advanced technologies. The company's "razor/razor blade" business model, centered on its Hydrafacial Delivery Systems and recurring consumables, aligns with the industry trend towards repeatable treatments and recurring revenue streams. The focus on clinically supported outcomes and personalized experiences, as seen with Syndeo and Boosters, positions the company to capitalize on consumer demand for effective and tailored solutions. However, the significant decrease in Delivery System sales suggests that macroeconomic headwinds are impacting capital equipment investments by providers, a trend StockSavvy.ai observes across the broader medical aesthetics sector during periods of economic uncertainty. The company's efforts to strengthen commercial execution and increase utilization of its installed base are critical in this environment, as competitors continue to innovate and new "indie" and "influencer-backed" brands emerge.

Comparison to Industry Standards

• The filing mentions competitors such as DiamondGlow, Dermasweep, Cartessa, OxyGeneo, Venus Glow, JetPeel, SaltFacial, and Glownar, which offer similar skin care and facial treatment products and services. However, specific comparative performance data (e.g., market share changes, revenue growth rates, profitability) for these competitors are not provided in the filing to assess the company's performance against industry standards.
• The company states it has approximately 60% U.S. market share in the microdermabrasion category, indicating a strong leadership position within this specific segment, but lacks broader market share data for the entire medical aesthetics industry for a comprehensive comparison.

Management Changes

Corporate Governance

Legal Proceedings

• **Cartessa Aesthetics, LLC (Patent Infringement)**: Hydrafacial filed a complaint in December 2020 alleging infringement of four patents. An appeal is ongoing in the Federal Circuit Court of Appeals, challenging a summary judgment of non-infringement on one patent, with a cross-appeal by Cartessa. Briefing is complete, and a hearing is expected later in 2026.
• **ITC Cartessa Matter (Patent Infringement)**: Hydrafacial filed a complaint in June 2024 against Cartessa and Eunsung. An initial determination issued in August 2025 found Hydrafacial's patent (U.S. Patent No. 11,865,287) valid and infringed, recommending an exclusion order and cease and desist order against Cartessa. A final determination is expected by the end of March 2026.
• **Second Cartessa Case (Patent Infringement)**: Filed in June 2024, this case is stayed pending the resolution of the ITC Cartessa Matter. Hydrafacial plans to reopen it to seek monetary damages after the ITC matter concludes.
• **Eunsung Global Corp (and Sinclair Pharma Ltd. and Aesthetic Management Partners, Inc.) IPRs**: Multiple inter partes review (IPR) petitions were filed challenging Hydrafacial's patents. Eunsung terminated its IPR proceedings in July 2025. Three remaining IPRs by Sinclair and AMP are instituted but stayed pending USPTO Director review related to the ITC Cartessa Matter. Hydrafacial plans to vigorously defend its patents.
• **Medicreations LLC (Patent Infringement)**: Hydrafacial filed a complaint in May 2024. A motion for preliminary injunction was denied in October 2025. The parties reached a settlement in principle in January 2026, and the case is expected to be dismissed by the end of March 2026.
• **Sinclair Pharma US, Inc (Patent Infringement)**: Hydrafacial filed a complaint in July 2024, which was stayed pending an ITC investigation (terminated in February 2025). Discovery is now proceeding, and Sinclair filed a motion to stay the case in view of the IPR proceedings. Hydrafacial will seek monetary damages.
• **Aesthetic Management Partners Inc. (Patent Infringement)**: Hydrafacial filed a complaint in July 2024, which was stayed due to an ITC investigation (terminated in February 2025). A motion for preliminary injunction was filed in June 2025, with no order yet. AMP filed a partial motion to dismiss and a motion to stay the case in view of the IPR proceedings. Hydrafacial will continue to seek monetary damages.
• **Medical Purchasing Resource, LLC (Trademark Infringement)**: Hydrafacial filed a complaint in June 2024. The parties reached a settlement agreement in April 2025, where Medical Purchasing Resource agreed to stop using Hydrafacial's trademarks and other unlawful activities, and to pay $105,000 for past damages. The case has been dismissed.
• **Luvo Medical Technologies Inc (Patent Infringement)**: Hydrafacial filed a complaint in August 2024. The case was settled in July 2025 with Eunsung agreeing to a consent judgment, and the case has been dismissed.
• **ITC Luvo Matter (Patent Infringement)**: Hydrafacial filed a complaint in August 2024. A settlement agreement was reached with Luvo and Healthcare Markets in March 2025, leading to the termination of the investigation for them and default judgment against the remaining respondents.
• **Med Spa Essentials, LLC (Trademark Infringement)**: Hydrafacial filed a complaint in March 2025. Med Spa Essentials agreed to shut down its business and stop unlawful acts. The case was dismissed in July 2025.
• **Candela Corp. (Patent Infringement)**: Hydrafacial filed a complaint in April 2025. The case is in its early stages of discovery, and Hydrafacial is seeking monetary damages.
• **BQ Aesthetix & Co., LLC (Patent Infringement)**: Hydrafacial filed a complaint in June 2025. The case is in its early stages of discovery, and Hydrafacial is seeking monetary damages.
• **Securities Class Action**: Filed in November 2023 against the company and certain officers, alleging misleading statements regarding Syndeo 1.0 and 2.0 device performance. Defendants' motion to dismiss was denied in September 2025. The case is currently in the discovery phase, with a trial set for December 7, 2027, and mediation to be completed by October 13, 2027. The company believes the claims have no merit.
• **Customer Class Action**: Filed in October 2024 against Hydrafacial and The Beauty Health Company, alleging defective Syndeo machines and misrepresentations. Most claims were dismissed in December 2025, except for breach of express warranty and certain New York consumer protection claims. A settlement-in-principle was reached in February 2026, with a motion for preliminary approval due by May 29, 2026. The company believes the claims have no merit.
• **Consolidated Derivative Action**: Filed in February/May 2024 against former CEO, CFO, and Board members, alleging breach of fiduciary duty, gross mismanagement, etc., related to Syndeo 1.0 and 2.0 devices. A settlement-in-principle was reached in November 2025, and the parties are finalizing settlement papers for court approval.
• **Securities and Exchange Commission (SEC) Subpoena**: The company was informed in January 2024 that the SEC is conducting a formal investigation related to allegations in the Securities Class Action lawsuit. The company is cooperating with the investigation, but the duration, scope, or outcome cannot be predicted at this time.

Related Party Transactions

• **Registration Rights Agreement**: Entered into on May 4, 2021, with BLS Investor Group LLC (Sponsor) and Hydrafacial Stockholders, granting them registration rights for their Class A Common Stock. The Sponsor also agreed to restrictions on the transfer of its securities for specified periods.
• **Investor Rights Agreement**: Entered into on May 4, 2021, with LCP Edge Holdco, LLC, granting LCP the right to designate a number of directors for appointment or election to the company's Board of Directors and its committees, based on its percentage ownership of outstanding Class A Common Stock (e.g., one director for at least 10%, two for at least 15%, three for at least 40%).

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings and the conversion of outstanding convertible notes. The ongoing SEC investigation and multiple class-action lawsuits introduce significant legal and reputational risks that could impact share price. No dividends are expected in the foreseeable future, meaning returns depend on stock price appreciation.
• **Customers (Providers)**: Are impacted by macroeconomic conditions, which have negatively affected their spending on Delivery Systems. They benefited from the Syndeo Enhancement Program, which upgraded older devices. Some customers are involved in a class-action lawsuit alleging defective Syndeo machines.
• **Employees**: Personnel-related expenses decreased in 2025, indicating potential workforce adjustments. Employees benefit from competitive compensation, comprehensive benefits, and talent development programs. The new Clawback Policy applies to officers and non-executive officers, increasing accountability.
• **Suppliers**: The company's reliance on single supply relationships for certain key components creates risk for suppliers if demand fluctuates or if the company seeks alternative sources. Macroeconomic pressures could also affect suppliers' costs and ability to deliver.
• **Creditors (Noteholders)**: Holders of the 2026 Notes face a near-term maturity in October 2026, with $124.5 million classified as current liabilities. Holders of the new 2028 Notes benefit from a higher interest rate (7.95%) but are subject to the company's ability to meet debt obligations and restrictive covenants.

Next Steps

• Vigorously defend patents against challenges in IPR proceedings (Sinclair and AMP IPRs) if they are unstayed.
• Reopen the Second Cartessa Case to seek monetary damages after the conclusion of the ITC Cartessa Matter.
• Continue to pursue claims against Sinclair and Viora in the Sinclair Case.
• Continue to seek monetary damages and vigorously pursue claims against AMP in the AMP Case.
• Finalize settlement papers for the Consolidated Derivative Action for submission to, and approval of, the Delaware Court of Chancery.
• Continue to respond to SEC subpoenas and fully cooperate with the SEC investigation.
• File necessary motion papers for preliminary approval of the settlement in the Customer Class Action on or before May 29, 2026.
• Evaluate capital expenditure needs based on revenue growth, potential acquisitions, research and development spending, international expansion, market acceptance, and overall economic conditions.
• Monitor and adapt to evolving legislative and regulatory activity related to artificial intelligence (AI).
• Continue to invest in new capabilities and the use of emerging technologies across various aspects of the business.
• Continue to build a strong and secure technology infrastructure, expand omnichannel capabilities, upgrade existing hardware and software, and utilize data-driven analytics to optimize supply and demand planning.
• Continue to review and refine data privacy, security, and AI-related policies to align with shifting regulatory standards.
• Monitor FDA announcements and guidance closely to ensure compliance with OTC drug regulations.
• Monitor the ongoing implementation timeline of MoCRA for cosmetics GMPs and prepare for compliance with forthcoming final rules.
• Monitor the legislative procedure for the European Commission's proposed amendments to the EU Medical Devices Regulation.

Key Dates

Recommendation

StockSavvy.ai recommends a "Hold" position. While the company demonstrated improved gross margins and reduced operating losses in 2025, the significant decline in Delivery System sales and modest consumables growth indicate persistent market challenges. The ongoing SEC investigation and multiple class-action lawsuits introduce substantial legal and reputational risks, creating an uncertain environment. The strategic debt restructuring is a positive step, but the overall financial performance and legal overhang warrant caution, suggesting investors should await clearer signs of sustained revenue growth and resolution of legal matters before considering a more aggressive stance.

Keywords

Beauty Health Company, Hydrafacial, SkinStylus, HydraScalp, medical aesthetics, skincare, microneedling, nano-channeling, consumables, delivery systems, SEC filing, 10-K, financial results, convertible notes, patent infringement, class action, regulatory compliance, FDA, EU MDR, ESG, cybersecurity, stock SKIN